中文摘要：
在睪丸中，間質巨噬細胞被認為在胎兒發(fā)育期間來源于卵黃囊，隨后被骨髓來源的巨噬細胞取代。相比之下，據報道圍小管巨噬細胞首先在出生后睪丸中出現，并且代表骨髓來源單核細胞的后代。在這里，我們使用高維單細胞分析定義了胎兒和出生后睪丸中新型的單核細胞和巨噬細胞類型。我們的結果顯示，間質巨噬細胞主要來源于胎肝衍生的前體細胞，而圍小管巨噬細胞則在出生時由胚胎前體細胞生成。我們發(fā)現，即使在系統(tǒng)性巨噬細胞耗竭后，骨髓來源的單核細胞也不會對睪丸巨噬細胞庫的補充做出顯著貢獻。胎兒期而非出生后存在的巨噬細胞對于正常的精子生成是必要的。因此，我們的多方面數據通過闡明睪丸巨噬細胞的分化、穩(wěn)態(tài)和功能，挑戰(zhàn)了當前睪丸巨噬細胞生物學的現有范式。
英文摘要：
In the testis, interstitial macrophages are thought to be derived from the yolk sac during fetal development, and later replaced by bone marrow-derived macrophages. By contrast, the peritubular macrophages have been reported to emerge first in the postnatal testis and solely represent descendants of bone marrow-derived monocytes. Here, we define new monocyte and macrophage types in the fetal and postnatal testis using high-dimensional single-cell analyses. Our results show that interstitial macrophages have a dominant contribution from fetal liver-derived precursors, while peritubular macrophages are generated already at birth from embryonic precursors. We find that bone marrow-derived monocytes do not substantially contribute to the replenishment of the testicular macrophage pool even after systemic macrophage depletion. The presence of macrophages prenatally, but not postnatally, is necessary for normal spermatogenesis. Our multifaceted data thus challenge the current paradigms in testicular macrophage biology by delineating their differentiation, homeostasis and functions.
論文信息：
論文題目：Generation, localization and functions of macrophages during the development of testis
期刊名稱：Nature Communications
時間期卷：11, Article number: 4375 (2020)
在線時間：2020年9月1日
DOI： doi.org/10.1038/s41467-020-18206-0
產品信息：
貨號：CP-005-005
規(guī)格：5ml+5ml
品牌：Liposoma
產地：荷蘭
名稱：Clodronate Liposomes&Control Liposomes
辦事處：Target Technology(靶點科技)
Clodronate Liposomes氯膦酸鹽脂質體聯合抗體清除骨髓，骨髓來源的血液單核，還有重點研究的部位睪丸巨噬細胞，荷蘭Liposoma巨噬細胞清除劑Clodronate Liposomes見刊于Nature Communications：睪丸發(fā)育過程中巨噬細胞的產生、定位及功能。
Liposoma巨噬細胞清除劑Clodronate Liposomes氯膦酸二鈉脂質體清除睪丸巨噬細胞的材料和方法：
Ten-day-old wild-type mice were treated with CSF1 neutralizing antibody and clodronate-containing liposomes to deplete tissue macrophages and blood monocytes. Intraperitoneal injection of CSF1 antibody (Bio X Cell, clone 5A1) or IgG1 isotype control (Bio X Cell, clone HRPN) (500?µg on the first cycle, 250?µg on the second and third cycles) was followed by intravenous administration of clodronate-containing or empty control liposomes (Liposoma; in 50?µl volume) on a subsequent day. Three consecutive treatment cycles were performed at three-day intervals. Tissues were harvested for flow cytometry and imaging analyses 40?h, 11 days, or 21 days after the last clodronate injection
材料和方法文獻截圖：
